Veracyte (VCYT) News
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
45.23+1.63 (+3.74%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
VCYT news summary
We found 29 recent headlines mentioning Veracyte (VCYT): 5 in the past week and 22 in the past 30 days, most often from Nasdaq. For price context, VCYT is up 3.74% at $45.23. The most recent story, "Reasons to Hold Veeva Systems Stock in Your Portfolio for Now", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Veracyte headlines
- Reasons to Hold Veeva Systems Stock in Your Portfolio for NowVEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.NasdaqVEEV, WST, GMED, VCYT
- Is it the Right Time to Add Phibro Stock to Your Portfolio?PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.NasdaqPAHC, ABT, GMED, VCYT
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesVEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.NasdaqVEEV, WST, GMED, VCYT
- Is This the Right Time to Add TMO Stock to Your Portfolio?Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.NasdaqTMO, GMED, PAHC, VCYT
- Veeva's OpenData to Help Servier Build a Global AI Data FoundationVEEV's OpenData deal with Servier across 80+ countries strengthens its Data Cloud role as life sciences firms scale AI and advanced analytics.NasdaqVEEV, WST, GMED, VCYT
- 10x Genomics Begins Atera Shipments as Spatial Biology Demand RisesTXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.NasdaqTXG, ISRG, GMED, VCYT
- Here's Why You Should Retain McKesson Stock in Your Portfolio for NowMcKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.NasdaqMCK, ISRG, GMED, VCYT
- Here's Why You Should Retain Revvity Stock in Your Portfolio for NowRVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.NasdaqRVTY, ISRG, GMED, VCYT
- Fresenius Medical Care Reshapes China Portfolio for Long-Term GrowthFMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.NasdaqFMS, ISRG, GMED, VCYT
- Here's Why You Should Retain BDX Stock in Your Portfolio for NowBecton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.NasdaqBDX, WST, GMED, VCYT
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsBDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.NasdaqBDSX, TMO, BIO, VCYT
- Veeva Unveils AI Study Builder Agent to Speed Clinical Trial SetupVEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.NasdaqVEEV, WST, GMED, VCYT
- Illumina Stock Surges 94.9% YTD: What's Behind the Rally?ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.NasdaqILMN, TFX, GMED, VCYT
- Veeva Unveils Falcon Router to Streamline Biopharma Case RoutingVEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.NasdaqVEEV, WST, GMED, VCYT
- Here's Why You Should Hold Stryker Stock in Your Portfolio for NowSYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.NasdaqSYK, ABT, GMED, VCYT
- Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDxNTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.NasdaqNTRA, ISRG, GMED, VCYT
- Should You Continue to Hold IDXX Stock in Your Portfolio?IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.NasdaqIDXX, TFX, GMED, VCYT
- Veeva Expands Amgen Partnership With Global Vault CRM Rollout PlanVEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.NasdaqAMGN, VEEV, GMED, VCYT
- Waters Launches BD FACSDiscover A7 for Advanced Flow CytometryWAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.NasdaqWAT, GMED, VCYT, INSP
- Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEXSYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.NasdaqSYK, GMED, VCYT, INSP
- IDEXX Stock Gains Following the Acquisition of CoVetIDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.NasdaqIDXX, TFX, GMED, VCYT
- BDX Deploys Vmax 160 to Advance Intelligent Pharmacy AutomationBD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.NasdaqBDX, WST, GMED, VCYT
- Here's Why You Should Retain Ecolab Stock in Your Portfolio NowECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.NasdaqECL, WST, GMED, VCYT
- Reasons to Retain Tandem Diabetes Stock in Your Portfolio NowTNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.NasdaqTNDM, ILMN, GMED, VCYT
- Here's Why You Should Retain Cencora Stock in Your Portfolio for NowCencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.NasdaqCOR, WST, GMED, VCYT
- Cencora Launches Cell and Gene Therapy Enablement for Health SystemsCOR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.NasdaqCOR, WST, GMED, VCYT
- Natera & Angiex Partner to Evaluate AGX101 Response With SignateraNTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.NasdaqNTRA, WST, GMED, VCYT
- Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.NasdaqIDXX, TFX, GMED, VCYT
- Should You Hold Edwards Lifesciences Stock in Your Portfolio?EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.NasdaqEW, TFX, GMED, VCYT